Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334979 | 0.79 | HCRTR1 (0.58) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL1334981 | 0.79 | HCRTR1 (0.58) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL31444317 | 0.78 | SLC5A2 (0.40) | HCRTR2HCRTR1RORCMEN1KMT2A | |
| SCHEMBL31444485 | 0.78 | RORC (0.39) | HCRTR2HCRTR1RORCMEN1KMT2A | |
| SCHEMBL31444354 | 0.77 | MEN1 (0.39) | HCRTR2HCRTR1MEN1KMT2ASLC5A1 | |
| SCHEMBL31444335 | 0.77 | SLC5A1 (0.41) | HCRTR2HCRTR1RORCMEN1KMT2A | |
| SCHEMBL25329990 | 0.75 | HCRTR1 (0.53) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL697331 | 0.75 | HCRTR1 (0.52) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL1459146 | 0.75 | HCRTR1 (0.52) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL3508819 | 0.75 | HCRTR1 (0.52) | HCRTR2HCRTR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |